H S Hochster

Summary

Affiliation: New York University
Country: USA

Publications

  1. ncbi Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group
    H Hochster
    Kaplan Cancer Center and New York University Medical Center, New York, and Albert Einstein College of Medicine, Bronx, NY, USA
    J Clin Oncol 17:2553-61. 1999
  2. pmc Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study
    Howard Hochster
    New York University Medical Center, New York, NY 10016, USA
    J Clin Oncol 27:1607-14. 2009
  3. doi Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study
    Howard S Hochster
    New York University Cancer Institute, 160 East 34th St, New York, NY 10016, USA
    J Clin Oncol 26:3523-9. 2008
  4. pmc Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study
    Howard Hochster
    Division of Medical Oncology, New York University School of Medicine, NYU Cancer Institute, NY 10016, USA
    Gynecol Oncol 108:500-4. 2008
  5. ncbi Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299
    Howard S Hochster
    New York University Cancer Institute, New York 10016, USA
    J Clin Oncol 25:5397-402. 2007
  6. ncbi Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer
    Howard S Hochster
    Department of Medicine, New York University Cancer Institute, New York, New York 10016, USA
    Semin Oncol 33:S8-14. 2006
  7. ncbi Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study
    Howard S Hochster
    NYU School of Medicine and Cancer Institute, 160 East 34th Street, New York, NY 10016, USA
    Gynecol Oncol 100:324-9. 2006
  8. ncbi The role of pemetrexed in the treatment of gastrointestinal malignancy
    Howard S Hochster
    New York University School of Medicine, New York 10016, USA
    Clin Colorectal Cancer 4:190-5. 2004
  9. ncbi Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group
    Howard Hochster
    New York University School of Medicine, 160 E 32nd St, New York, NY 10016, USA
    J Clin Oncol 22:120-6. 2004
  10. ncbi Activity and safety of vinorelbine combined with doxorubicin or fluorouracil as first-line therapy in advanced breast cancer: a stratified phase II study
    H S Hochster
    New York University Medical Center, 160 East 32nd Street, New York, NY 10016 6004, USA
    Oncologist 6:269-77. 2001

Research Grants

Collaborators

Detail Information

Publications36

  1. ncbi Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group
    H Hochster
    Kaplan Cancer Center and New York University Medical Center, New York, and Albert Einstein College of Medicine, Bronx, NY, USA
    J Clin Oncol 17:2553-61. 1999
    ....
  2. pmc Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study
    Howard Hochster
    New York University Medical Center, New York, NY 10016, USA
    J Clin Oncol 27:1607-14. 2009
    ..To determine if maintenance rituximab (MR) after standard chemotherapy improves progression-free survival (PFS) in advanced-stage indolent lymphoma...
  3. doi Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study
    Howard S Hochster
    New York University Cancer Institute, 160 East 34th St, New York, NY 10016, USA
    J Clin Oncol 26:3523-9. 2008
    ..To evaluate the safety and efficacy of three oxaliplatin and fluoropyrimidine regimens, with or without bevacizumab, as first-line treatment for metastatic colorectal cancer (CRC)...
  4. pmc Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study
    Howard Hochster
    Division of Medical Oncology, New York University School of Medicine, NYU Cancer Institute, NY 10016, USA
    Gynecol Oncol 108:500-4. 2008
    ..Topotecan 14-day infusion combined with cisplatin was highly active in ovarian cancer, but too myelosuppressive. We therefore sought to evaluate the feasibility of substituting oxaliplatin for cisplatin to improve safety...
  5. ncbi Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299
    Howard S Hochster
    New York University Cancer Institute, New York 10016, USA
    J Clin Oncol 25:5397-402. 2007
    ..To evaluate the tolerability and effectiveness of uracil-tegafur (UFT) with leucovorin (LV) in the treatment of elderly patients with advanced colorectal cancer...
  6. ncbi Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer
    Howard S Hochster
    Department of Medicine, New York University Cancer Institute, New York, New York 10016, USA
    Semin Oncol 33:S8-14. 2006
    ..The survival advantages in patients with metastatic colorectal cancer with the addition of bevacizumab to chemotherapy support the use of this agent in first-line treatment...
  7. ncbi Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study
    Howard S Hochster
    NYU School of Medicine and Cancer Institute, 160 East 34th Street, New York, NY 10016, USA
    Gynecol Oncol 100:324-9. 2006
    ..To determine the toxicity and efficacy of combined therapy with cisplatin and prolonged infusion topotecan as front line therapy in women with epithelial ovarian cancer...
  8. ncbi The role of pemetrexed in the treatment of gastrointestinal malignancy
    Howard S Hochster
    New York University School of Medicine, New York 10016, USA
    Clin Colorectal Cancer 4:190-5. 2004
    ..Nonetheless, pemetrexed has important promise for new and improved regimens in the therapy of gastrointestinal cancer...
  9. ncbi Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group
    Howard Hochster
    New York University School of Medicine, 160 E 32nd St, New York, NY 10016, USA
    J Clin Oncol 22:120-6. 2004
    ..To determine the antitumor activity of the novel topoisomerase I inhibitor 9-aminocamptothecin (9-AC) given over 72 hours every 2 weeks in patients with ovarian carcinoma previously treated with one platinum-containing regimen...
  10. ncbi Activity and safety of vinorelbine combined with doxorubicin or fluorouracil as first-line therapy in advanced breast cancer: a stratified phase II study
    H S Hochster
    New York University Medical Center, 160 East 32nd Street, New York, NY 10016 6004, USA
    Oncologist 6:269-77. 2001
    ..The regimens were repeated every 21 days until evidence of progression of disease or severe toxicity...
  11. ncbi Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer
    Howard Hochster
    NYU School of Medicine, 160 East 32nd St, New York, NY 10016, USA
    J Clin Oncol 21:2703-7. 2003
    ..To determine the activity of biweekly oxaliplatin, combined with weekly bolus fluorouracil (FU) and low-dose leucovorin (LV) chemotherapy (bFOL), as first-line therapy for patients with metastatic colorectal cancer...
  12. ncbi Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up--a report from the Eastern Cooperative Oncology Group
    H S Hochster
    New York University, New York, NY, USA
    J Clin Oncol 18:987-94. 2000
    ..To determine the toxicity and recommended phase II doses of the combination of fludarabine plus cyclophosphamide in chemotherapy-naive patients with low-grade lymphoma...
  13. ncbi Newer approaches to gemcitabine-based therapy of pancreatic cancer: fixed-dose-rate infusion and novel agents
    Howard S Hochster
    Division of Medical Oncology, New York University School of Medicine, New York, NY 10016, USA
    Int J Radiat Oncol Biol Phys 56:24-30. 2003
    ..Because none of the new compounds investigated has as yet shown improvement compared with single-agent gemcitabine in prospectively randomized trials, gemcitabine remains the standard of care in pancreatic cancer...
  14. ncbi Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer
    Nancy Kemeny
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:4753-61. 2004
    ..This multicenter study evaluated FU/LV with or without oxaliplatin in patients with metastatic CRC after disease progression on sequential fluoropyrimidine and irinotecan...
  15. ncbi Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer
    Deepu Mirchandani
    New York University School of Medicine, New York, New York 10016, USA
    Clin Cancer Res 11:5912-9. 2005
    ..Other specific aims were preliminary assessment of activity in advanced ovarian and tubal malignancies, pharmacokinetics of oral topotecan, and correlation of response with topoisomerase I and II expression in tumors...
  16. ncbi Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study
    Elliot Newman
    Department of Surgery, New York University School of Medicine, and the NYU Cancer Institute, New York, NY, USA
    Semin Oncol 32:S97-100. 2005
    ..The data suggest that an approach consisting of systemic induction therapy, curative surgery with high R0 resection rates, and IP adjuvant therapy has acceptable toxicity and encouraging survival outcomes...
  17. ncbi Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days
    Franco M Muggia
    NYU Cancer Institute, Division of Medical Oncology, New York University School of Medicine, New York, NY 10016, USA
    Anticancer Drugs 13:819-25. 2002
    ..A dose of 9 mg/m(2)/cycle administered in a schedule of six divided fractions is suitable for further evaluation against tumors involving primarily the peritoneal cavity...
  18. doi Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study
    Peter S Kozuch
    Continuum Cancer Centers of New York, St Luke s Roosevelt Hospital, New York, NY, USA
    J Clin Oncol 26:2320-6. 2008
    ..To evaluate the efficacy and toxicity of bortezomib with or without irinotecan, in patients with relapsed or refractory colorectal cancer (CRC)...
  19. ncbi A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor
    Anna C Pavlick
    Division of Medical Oncology, Department of Medicine, Kaplan Cancer Center, NYU Cancer Institute, New York University Medical Center, 462 First Avenue, BCD Room 556, New York, NY 10016, USA
    Anticancer Drugs 15:119-25. 2004
    ..Our observations should provide evidence for phase II studies of this combination in patients with breast cancer and other anthracycline/taxane-sensitive cancers...
  20. ncbi Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer
    Elliot Newman
    Department of Surgery, New York University School of Medicine, New York, New York 10016, USA
    J Gastrointest Surg 6:212-23; discussion 223. 2002
    ..We conclude that CPT-11-based neoadjuvant therapy downstages locally advanced gastric cancer. Further follow-up is necessary to determine the ultimate impact of this combination therapy on recurrence and survival...
  21. ncbi Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer
    Howard Hochster
    Cancer Institute, New York University Medical Center, 160 East 34th Street, 9th Floor, New York, NY 10016, USA
    Clin Colorectal Cancer 5:257-62. 2005
    ..The distinct mechanisms of action and patterns of resistance displayed by pemetrexed and irinotecan make them attractive agents for combination therapy...
  22. ncbi A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer
    Ramesh K Ramanathan
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Chemother Pharmacol 61:453-8. 2008
    ..Based on preclinical data that milataxel may be active in colorectal cancer (CRC), a phase II study was performed in patients with advanced previously treated CRC...
  23. ncbi The role of pemetrexed in the treatment of colorectal cancer
    Howard Hochster
    Division of Medical Oncology, New York University School of Medicine, NY 10016, USA
    Semin Oncol 29:54-6. 2002
    ..Combinations of pemetrexed with irinotecan and oxaliplatin have also proven feasible. Pemetrexed is a promising new drug for the treatment of colorectal cancer...
  24. ncbi Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies
    Missak Haigentz
    Albert Einstein Comprehensive Cancer Center, Montefiore Medical Center, Bronx, NY, USA
    Anticancer Drugs 14:321-6. 2003
    ..We conclude that amifostine, at 740 mg/m2, does not lead to less myelosuppression when combined with gemcitabine/cisplatin chemotherapy regimens and may possibly contribute to subjective intolerance...
  25. ncbi Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors
    Sridhar Mani
    Albert Einstein College of Medicine, Department of Molecular Pharmacology, and Albert Einstein Comprehensive Cancer Center, Bronx, New York 10461, USA
    Clin Cancer Res 10:1289-98. 2004
    ..The purpose of this study was to determine the maximum tolerated dose, toxicity, and pharmacokinetics of BMS-247550 administered as a 1-h i.v. infusion every 3 weeks...
  26. pmc Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma
    Anthony P Lam
    New York Cancer Consortium www newyorkcancerconsortium org, including the Montefiore Einstein Cancer Center, Bronx, NY 10461, USA
    Am J Clin Oncol 33:121-4. 2010
    ..To determine the efficacy and toxicity of the protein kinase C inhibitor bryostatin-1 plus paclitaxel in patients with advanced pancreatic carcinoma...
  27. pmc Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors
    Anna C Pavlick
    New York University School of Medicine, New York University Cancer Institute, New York, NY, USA
    Cancer Chemother Pharmacol 64:803-10. 2009
    ..We designed a phase I study to achieve tolerable doses and schedules of bryo and cisplatin in combination and in this sequence...
  28. doi Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma
    Jennifer Wu
    Department of Medical Oncology, NYU School of Medicine, New York, NY, USA
    Invest New Drugs 28:670-6. 2010
    ..Darinaparsin is a novel organic arsenic that reaches higher intracellular concentration with decreased toxicity compared to inorganic arsenic. We conducted a multi-center phase II study with darinaparsin in patients with advanced HCC...
  29. ncbi Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma
    Minaxi Jhawer
    Montefiore Medical Center, NY, USA
    Invest New Drugs 25:85-94. 2007
    ..To evaluate the tolerability and efficacy of nolatrexed in patients with advanced hepatocellular carcinoma...
  30. ncbi Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study
    Leonard B Saltz
    Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:4557-61. 2007
    ..We evaluated the safety and efficacy of concurrent administration of two monoclonal antibodies, cetuximab and bevacizumab, in patients with metastatic colorectal cancer...
  31. ncbi Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer
    Deirdre J Cohen
    Department of Medicine, NYU Clinical Cancer Center, New York, NY 10016, USA
    Clin Colorectal Cancer 7:S21-7. 2007
    ....
  32. ncbi Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer
    Howard S Hochster
    Department of Medicine Clinical Pharmacology, New York University Cancer Institute, New York, New York, USA
    Cancer 107:676-85. 2006
    ..Other targeted therapies also are considered for future clinical trials. Based on a comprehensive review of past trials, a consensus on endpoints in the treatment of pancreatic cancer and an approach to new trials is presented...
  33. ncbi Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Con: Pumpin' FU (or, avoiding that oral fixation)
    Howard S Hochster
    New York University Cancer Center, New York, NY 10016, USA
    Clin Adv Hematol Oncol 3:405-6. 2005
  34. ncbi Opportunities for newer agents in combination with oxaliplatin
    Howard S Hochster
    Department of Medicine, NYU School of Medicine, New York, NY 10016, USA
    Semin Oncol 30:62-7. 2003
    ..The rationale for combinations with oxaliplatin and early clinical trial results are discussed...
  35. ncbi Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity
    Howard S Hochster
    J Clin Oncol 25:4028-9. 2007
  36. ncbi Recent developments in the clinical activity of topoisomerase-1 inhibitors
    Max Kreditor
    Cancer Chemother Biol Response Modif 22:61-100. 2005

Research Grants4

  1. Pharmacodynamics of Gemcitabine by MRS in Pancreatic CA
    Howard Hochster; Fiscal Year: 2005
    ....
  2. Pharmacodynamics of Gemcitabine by MRS in Pancreatic CA
    Howard Hochster; Fiscal Year: 2006
    ....
  3. Pharmacodynamics of Gemcitabine by MRS in Pancreatic CA
    Howard Hochster; Fiscal Year: 2007
    ....